Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: A retrospective study from the société française de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Haematologica

Volumn 97, Issue 4, 2012, Pages 482-490

  Fabre, Claire ^a,b   Koscielny, Serge ^a,b   Mohty, Mohamad ^c   Fegueux, Nathalie ^d   Blaise, Didier ^e   Maillard, Natacha ^f   Tabrizi, Reza ^g   Michallet, Mauricette ^h   Socié, Gérard ⁱ   Yakoub Agha, Ibrahim ^j   Garban, Frédéric ^k   Uzunov, Madalina ^l   François, Sylvie ^m   Contentin, Nathalie ⁿ   Lapusan, Simona ^o   Bourhis, Jean Henri ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d HÔPITAL SAINT ELOI   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k GRENOBLE UNIVERSITY HOSPITAL   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m ANGERS UNIVERSITY HOSPITAL   (France)

ⁿ CENTRE HENRI BECQUEREL   (France)

^o Service d'Hématologie A   (France)

more..

Author keywords

Multiple myeloma; Tandem autologous allogeneic transplantation

Indexed keywords

BORTEZOMIB; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER PROGNOSIS; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; MULTIPLE MYELOMA; MYCOSIS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN OCCLUSION; VIRUS INFECTION; WHOLE BODY RADIATION;

ADULT; AGE FACTORS; AGED; CAUSE OF DEATH; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MORBIDITY; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859475998     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049742     Document Type: Article

References (35)

1. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versusmyeloma effect: proof of principle. Blood. 1996;87(3):1196-1198.
2. Aschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton G. Graft-versus-myeloma effect. Lancet. 1996;348(9023):346.
3. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 2000;18(23):3918-3924.
4. Carella AM, Beltrami G, Corsetti MT, Scalzulli P, Carella AM Jr, Musto P. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity. Haematologica. 2004;89(12):1534-1536.
5. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective casematched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88(12):4711-4718.
6. Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM, Huff CA. A phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant. 2009;15(1):83-91.
7. Kroger N. Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma. 2005;46(6):813-821.
8. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009;113(14):3383-3391.
9. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102(9):3447-3454.
10. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100(3):755-760.
11. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood. 2009;113(14):3375-3382.
12. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dosereduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474-3480.
13. Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, et al. Long-term followup results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008;112(9):3914-3915.
14. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl JMed. 2007;356(11):1110-1120.
15. Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591-3593.
16. Stadtmauer E, Krishnan A, Pasquini M, Ewell M, Alyea E, Antin J, et al. Tandem autologous stem cell transplants (auto-auto) with or without maintenance therapy versus single autologous transplant followed by HLA-Matched sibling non- myeloablative allogeneic stem cell transplant (autoallo) for patients (pts) with high risk (HR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial. ASH Annual Meeting Abstracts 2010 116:526.
17. Krishnan A, Pasquini M, Ewell M, Stadtmauer E, Alyea E, Antin J, et al. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non-myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial ASH Annual Meeting. Abstracts 2010 116:41.
18. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29 (22):3016-3022.
19. Knop S LP, Hebart H, and et al. Allogeneic stem cell transplant versus tandem highdose melphalan for front-line treatment of deletion 13q14 myeloma: an interim analysis of the German DSMM V trial. Blood. 2009;114: Abstract 51.
20. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.
21. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-1473.
22. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
23. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3): 250-259.
24. Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Stat Med. 1994;13(21):2233-2247.
25. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002;100(12):3919-3924.
26. Karlin L, Arnulf B, Chevret S, Ades L, Robin M, De Latour RP, et al. Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy. Bone Marrow Transplant. 2011;46(2):250-256.
27. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010; 28(30):4621-4629.
28. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21(1):151-157.
29. Mehta J, Gordon LI, Tallman MS, Winter JN, Evens AM, Frankfurt O, et al. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant. 2006;38(2):95-100.
30. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98(7):2043-2051.
31. Harrison DE, Astle CM. Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure. J Exp Med. 1982;156(6):1767-1779.
32. Liang Y, Van Zant G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood. 2005;106(4):1479-1487.
33. Kamminga LM, van Os R, Ausema A, Noach EJ, Weersing E, Dontje B, et al. Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. Stem Cells. 2005;23(1):82-92.
34. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686.
35. van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood. 2006;107(8):3415-3416.